Stock Movers T-Mobile Falls, MGM Rises, Incyte Gains on Clinical Data
Jun 16, 2025
T-Mobile faces a dip as the Trump-branded mobile service announcement shakes investor confidence. Meanwhile, MGM sees a boost thanks to its BetMGM joint venture, which raised revenue forecasts after impressive second-quarter results. Incyte enjoys gains following promising clinical trial data for its new blood disorder therapy, capturing Wall Street's attention. The episode delves into how these market movements reflect broader trends and sentiments in the investment landscape.
AI Snips
Chapters
Transcript
Episode notes
T-Mobile's Market Resilience
- T-Mobile faces potential competition from a Trump-branded mobile service relying on American-made hardware.
- Despite this, T-Mobile's 5G leadership should support a 4.5% CAGR in sales over the next three years.
MGM Sports Betting Growth
- MGM's BetMGM joint venture raised its net revenue and EBITDA guidance for fiscal 2025.
- This upward revision follows strong second-quarter performance in the sports betting segment.
Incyte's Clinical Data Boost
- Incyte impressed Wall Street with clinical trial data showing no dose-limiting toxicities and high treatment retention.
- Analysts upgraded Incyte, optimistic about its experimental therapy for a blood disorder.